608 related articles for article (PubMed ID: 30560866)
1. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.
Jia Q; Wu W; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ; Zhu B
Nat Commun; 2018 Dec; 9(1):5361. PubMed ID: 30560866
[TBL] [Abstract][Full Text] [Related]
2. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
[TBL] [Abstract][Full Text] [Related]
3. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
4. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
6. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.
Chen M; Chen R; Jin Y; Li J; Hu X; Zhang J; Fujimoto J; Hubert SM; Gay CM; Zhu B; Tian Y; McGranahan N; Lee WC; George J; Hu X; Chen Y; Wu M; Behrens C; Chow CW; Pham HHN; Fukuoka J; Wu J; Parra ER; Little LD; Gumbs C; Song X; Wu CJ; Diao L; Wang Q; Cardnell R; Zhang J; Wang J; Le X; Gibbons DL; Heymach JV; Jack Lee J; William WN; Cheng C; Glisson B; Wistuba I; Andrew Futreal P; Thomas RK; Reuben A; Byers LA; Zhang J
Nat Commun; 2021 Nov; 12(1):6655. PubMed ID: 34789716
[TBL] [Abstract][Full Text] [Related]
7. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
8. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor immune response varies among individuals: A gene expression profiling of mouse melanoma.
Yang X; Ma Z; Zhang Y; Wu J; Huang J; Zhao W; Mo F; Lin Z; Xu Y; Zhou Z; Chen S
Int Immunopharmacol; 2020 Mar; 80():106211. PubMed ID: 31972424
[TBL] [Abstract][Full Text] [Related]
10. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
AbdulJabbar K; Raza SEA; Rosenthal R; Jamal-Hanjani M; Veeriah S; Akarca A; Lund T; Moore DA; Salgado R; Al Bakir M; Zapata L; Hiley CT; Officer L; Sereno M; Smith CR; Loi S; Hackshaw A; Marafioti T; Quezada SA; McGranahan N; Le Quesne J; ; Swanton C; Yuan Y
Nat Med; 2020 Jul; 26(7):1054-1062. PubMed ID: 32461698
[TBL] [Abstract][Full Text] [Related]
11. Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma.
Seo JS; Lee JW; Kim A; Shin JY; Jung YJ; Lee SB; Kim YH; Park S; Lee HJ; Park IK; Kang CH; Yun JY; Kim J; Kim YT
Cancer Immunol Res; 2018 Jul; 6(7):848-859. PubMed ID: 29720381
[TBL] [Abstract][Full Text] [Related]
12. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
[No Abstract] [Full Text] [Related]
13. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
14. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen-directed immune escape in lung cancer evolution.
Rosenthal R; Cadieux EL; Salgado R; Bakir MA; Moore DA; Hiley CT; Lund T; Tanić M; Reading JL; Joshi K; Henry JY; Ghorani E; Wilson GA; Birkbak NJ; Jamal-Hanjani M; Veeriah S; Szallasi Z; Loi S; Hellmann MD; Feber A; Chain B; Herrero J; Quezada SA; Demeulemeester J; Van Loo P; Beck S; McGranahan N; Swanton C;
Nature; 2019 Mar; 567(7749):479-485. PubMed ID: 30894752
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
17. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancers.
Zhang JT; Dong S; Ji LY; Zhou JY; Chen ZH; Su J; Zhu QG; Wang MM; Ke EE; Sun H; Li XT; Yang JJ; Zhou Q; Zhang XC; Gao X; Yang XN; Xia X; Yi X; Zhong WZ; Wu YL
Thorac Cancer; 2022 May; 13(9):1333-1341. PubMed ID: 35394115
[TBL] [Abstract][Full Text] [Related]
19. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
